Peptipedia
Anti-AgingPreclinicalAnimal Studies

FOXO4-DRI

Also known as FOX04-DRI, FOXO4 D-Retro-Inverso, Proxofim

A senolytic peptide designed to selectively eliminate senescent cells by disrupting the FOXO4-p53 interaction. Shows promise for restoring tissue function in aging.

Preclinical - Extensive animal research, Phase 1 trials planned
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

2-10 mg every other day for 3 doses (one cycle)

Frequency

3 doses every other day, 1-3 cycles per year

Duration

1 cycle = 3 doses over 5-6 days

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 2-10 mg every other day for 3 doses (one cycle) via Subcutaneous injection, 3 doses every other day, 1-3 cycles per year. Dose range: 2-10 mg per dose. Duration: 1 cycle = 3 doses over 5-6 days.

Timing & Administration

Administer via Subcutaneous injection. Frequency: 3 doses every other day, 1-3 cycles per year.

Mechanism of Action

Interferes with binding between FOXO4 and p53 proteins. Competes for this binding in senescent cells, releasing p53 to trigger apoptosis while sparing healthy cells.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical - Extensive animal research, Phase 1 trials planned.

Side Effects & Safety

Important Warnings

  • Limited human safety data
  • Phase 1 trials planned.
Injection site reactions
fatigue
muscle soreness
nausea

References

No references available.

Related Peptides

Browse all →
DSIPAnti-Aging

A peptide studied for its ability to promote deep sleep and modulate stress hormones.

View profile
HumaninAnti-Aging

A mitochondria-derived peptide discovered for its neuroprotective effects against Alzheimer's-related toxicity.

View profile
NAD+ PrecursorsAnti-Aging

While not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.

View profile